FILTER
LATEST INTERVIEWS
Dolores Biamou
MINING PROJECTS DIRECTOR AFRICA, BOLLORÉ LOGISTICS
Bolloré Logistics explains how it has been able to maintain the supply chain for mines in Africa despite the pandemic and security threats.
Michael White
PRESIDENT AND CEO, IBK CAPITAL
IBK Capital outlines the current trends in mining investments.
Aldimir Torres
PRESIDENT, MEXICO’S NATIONAL ASSOCIATION OF PLASTIC INDUSTRIES (ANIPAC)
ANIPAC explains its mission is to promote the competitiveness and sustainability of the Mexican plastics industry.
Mark Bristow
PRESIDENT AND CEO, BARRICK GOLD
Mark Bristow spoke with GBR about Barrick’s global operations and sustainability philosophy.
Ricardo Méndez Pastrana
DIRECTOR GENERAL, PROMAPLAST
Chemical distributor PromaPlast details the milestones achieved on its 25th anniversary.
Marco Mastrodonato
FOUNDER AND CEO, BMG PHARMA
BMG explains the potential of its modified hyaluronic acid technology.
Omar Alessandrini
CEO, Biomedical Pharma
Biomedical Pharma explains the huge scope for its photocatalytic cleaning products.
Laurent Piat
MANAGING DIRECTOR, VEOLIA GHANA
Veolia designs and provides solutions for water, waste and energy management.
Bernard Kaninda
REGIONAL DIRECTOR AFRICA, MAXAM
Maxam describes its services and the current opportunities in West Africa.
Deon de Kock
PRESIDENT, SUB-SAHARAN AFRICA, MIDDLE EAST & SOUTH ASIA, FLSMIDTH
FLSmidth is an international supplier of sustainable solutions and services to the global cement and mining industries.
MACIG
SPANISH
SUBSCRIBE TO OUR NEWSLETTER
RECENT PUBLICATIONS
United States Life Sciences 2025 - Digital Interactive
Resilience amid uncertainty. These words encapsulate the US life sciences sector as it navigates 2025. While the industry has largely rebounded from the recent biotech bear market, with clinical trial starts and funding showing signs of rebound, headwinds remain.
Resilience amid uncertainty. These words encapsulate the US life sciences sector as it navigates 2025. While the industry has largely rebounded from the recent biotech bear market, with clinical trial starts and funding showing signs of rebound, headwinds remain.
PARTNER EVENTS
SUBSCRIBE TO OUR
NEWSLETTER
- Get GBR content delivered to your inbox
- Receive industry based news
- Completely free, e-mail only
